2020
PET Imaging of Synaptic Vesicle Protein 2A
Finnema S, Li S, Cai Z, Naganawa M, Chen M, Matuskey D, Nabulsi N, Esterlis I, Holmes S, Radhakrishnan R, Toyonaga T, Huang Y, Carson R. PET Imaging of Synaptic Vesicle Protein 2A. 2020, 993-1019. DOI: 10.1007/978-3-030-53176-8_29.ChaptersSynaptic vesicle protein 2APositron emission tomographyAntiepileptic drug levetiracetamInitial PET studiesPET imagingPET studiesSynaptic densityDrug levetiracetamHigh-affinity SV2A ligandsBrain regionsSynaptic density lossNeuropathological diseasesDisease-modifying therapiesLarge patient cohortMajor depressive disorderProtein 2APET imaging resultsPosttraumatic stress disorderPatient groupPatient cohortDepressive disorderClinical valueParkinson's diseaseEfficacy assessmentSynaptic vesicle proteins
2001
Analyses of [18F]altanserin bolus injection PET data. II: Consideration of radiolabeled metabolites in humans
Price J, Lopresti B, Meltzer C, Smith G, Mason N, Huang Y, Holt D, Gunn R, Mathis C. Analyses of [18F]altanserin bolus injection PET data. II: Consideration of radiolabeled metabolites in humans. Synapse 2001, 41: 11-21. PMID: 11354009, DOI: 10.1002/syn.1055.Peer-Reviewed Original ResearchConceptsBlood-brain barrierPositron emission tomographyPrevious animal studiesAntagonist radiotracersPET dataBolus injectionAnimal studiesReference tissue methodEmission tomographyPET studiesArterial inputTissue measuresConstant radioactivityLogan analysisFurther studiesHigh-performance liquid chromatography analysisRadiometabolitesTissue methodLiquid chromatography analysisMetabolitesInjectionBolusAnalyses of [18F]altanserin bolus injection PET data. I: Consideration of radiolabeled metabolites in baboons
Price J, Lopresti B, Mason N, Holt D, Huang Y, Mathis C. Analyses of [18F]altanserin bolus injection PET data. I: Consideration of radiolabeled metabolites in baboons. Synapse 2001, 41: 1-10. PMID: 11354008, DOI: 10.1002/syn.1054.Peer-Reviewed Original ResearchConceptsBolus injectionMajor radiometabolitePositron emission tomographySerotonin 2A receptor bindingBlood-brain barrier passageReceptor-rich regionsKetanserin administrationNonspecific radioactivityReceptor blockadeInput function methodEmission tomographyPET studiesPET dataReceptor bindingRadiometabolitesVivo kineticsInjectionBBBTissue componentsHuman brainBaboonsMetabolitesRadioactivityBlockadeAntagonist
1998
Chapter 44 Characterization of the Radiolabeled Metabolites of [18F]Altanserin Implications for Kinetic Modeling
Lopresti B, Holt D, Mason N, Huang Y, Ruszkiewicz J, Perevuznik J, Price J, Smith G, Davis J, Mathis C. Chapter 44 Characterization of the Radiolabeled Metabolites of [18F]Altanserin Implications for Kinetic Modeling. 1998, 293-298. DOI: 10.1016/b978-012161340-2/50046-9.Peer-Reviewed Original ResearchVivo positron emission tomography (PET) imaging studiesPositron emission tomography (PET) imaging studiesTomography Imaging StudyPostmortem brain studiesSerotonergic abnormalitiesSerotonergic dysfunctionMajor depressionRadiolabeled metabolitesTherapeutic efficacyAlzheimer's diseaseImaging studiesNeurodegenerative disordersPET studiesReceptorsBrain studiesVivo propertiesDiseaseRadioligandDisordersDysfunctionAltanserinAbnormalitiesNonspecific bindingSchizophreniaChapter 64 [18F]Altanserin PET Studies of Serotonin-2A Binding Examination of Nonspecific Component
Price J, Lopresti B, Mason N, Huang Y, Holt D, Smith G, Mathis C. Chapter 64 [18F]Altanserin PET Studies of Serotonin-2A Binding Examination of Nonspecific Component. 1998, 427-434. DOI: 10.1016/b978-012161340-2/50066-4.Peer-Reviewed Original Research